ModeX Therapeutics Doses First Patients in Trial of Novel Tetraspecific Therapy for B-Cell Lymphoma
ModeX Therapeutics initiates clinical testing of MDX2003, a next-generation multispecific antibody therapy designed to enhance immune response and improve outcomes in B-cell lymphoma patients.
ModeX Therapeutics | 24/04/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy